Literature DB >> 6319748

Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons.

C W Czarniecki, C W Fennie, D B Powers, D A Estell.   

Abstract

The antiviral and antiproliferative effects of highly purified Escherichia coli-derived human interferons (IFNs) were examined in human melanoma cells (Hs294T). Antiproliferative activity was monitored by measuring inhibition of cell multiplication, and antiviral activity was determined by inhibition of herpes simplex virus type 1 replication. Treatment of cells with IFN-gamma in combination with IFN-alpha A or IFN-beta 1 resulted in potentiation of both antiproliferative and antiviral activities. In contrast, combination treatments composed of IFN-alpha A and IFN beta 1 yielded inconsistent results. Some combinations reflected additive responses, whereas others were antagonistic. To examine correlations between IFN-induced biological activities and interactions of the different IFNs with cell surface receptors, in vivo [35S]methionine-labeled IFN-alpha A was prepared. Binding studies indicated the presence of 2,980 +/- 170 receptors per cell, each with an apparent Kd of (8.4 +/- 1.3) X 10(-11) M. Results from competitive binding studies suggested that Hs294T cells possess at least two types of IFN receptors: one which binds IFN-alpha A and IFN-beta 1 and another to which IFN-gamma binds.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319748      PMCID: PMC255490     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Synergistic activities of type I (alpha, beta) and type II (gamma) murine interferons.

Authors:  A Zerial; A G Hovanessian; S Stefanos; K Huygen; G H Werner; E Falcoff
Journal:  Antiviral Res       Date:  1982-09       Impact factor: 5.970

3.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

4.  Specific binding of 125I-human interferon-gamma to high affinity receptors on human fibroblasts.

Authors:  P Anderson; Y K Yip; J Vilcek
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

5.  High-affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. IV. Mouse gamma interferon and cholera toxin do not compete for the common receptor site of alpha / beta interferon.

Authors:  M Aguet; F Belardelli; B Blanchard; F Marcucci; I Gresser
Journal:  Virology       Date:  1982-03       Impact factor: 3.616

6.  Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence.

Authors:  W R Fleischmann
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

7.  Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon.

Authors:  J L Crane; L A Glasgow; E R Kern; J S Youngner
Journal:  J Natl Cancer Inst       Date:  1978-09       Impact factor: 13.506

8.  Properties of a human alpha-interferon purified from E. coli extracts.

Authors:  R Wetzel; L J Perry; D A Estell; N Lin; H L Levine; B Slinker; F Fields; M J Ross; J Shively
Journal:  J Interferon Res       Date:  1981

9.  Action of murine gamma (immune)interferon on beta (fibroblast)-interferon resistant L 1210 and embryonal carcinoma cells.

Authors:  A G Hovanessian; C La Bonnardiere; E Falcoff
Journal:  J Interferon Res       Date:  1980

10.  Biological properties of human melanoma cells in culture.

Authors:  A A Creasey; H S Smith; A J Hackett; K Fukuyama; W L Epstein; S H Madin
Journal:  In Vitro       Date:  1979-05
View more
  51 in total

1.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 2.  The cellular receptor of the alpha-beta interferons.

Authors:  K E Mogensen; G Uzé; P Eid
Journal:  Experientia       Date:  1989-06-15

3.  DNA protein interactions at the interferon-responsive promoter elements: potential for an H-DNA conformation.

Authors:  C Roy; B Lebleu
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

4.  Posttranscriptional regulation of beta interferon expression in erythroid Friend cells treated with gamma interferon.

Authors:  G Marziali; G Fiorucci; E M Coccia; Z Percario; J Raber; A Battistini; G B Rossi; E Affabris; G Romeo
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Regulation of synthesis and turnover of an interferon-inducible mRNA.

Authors:  J Kusari; G C Sen
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

6.  In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs.

Authors:  Timothy M E Davis; Juliana Hamzah; Kenneth F Ilett; Harin A Karunajeewa; John C Reeder; Kevin T Batty; Sara Hackett; P Hugh R Barrett
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

7.  Beta and gamma interferons act synergistically to produce an antiviral state in cells resistant to both interferons individually.

Authors:  J A Lewis; A Huq; B Shan
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Mechanism of interferon action: alpha and gamma interferons differentially affect mRNA levels of the catalytic subunit of protein kinase A and protein Mx in human cells.

Authors:  D C Thomas; C E Samuel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Tissue selectivity of interferon-stimulated gene expression in mice infected with Dam(+) versus Dam(-) Salmonella enterica serovar Typhimurium strains.

Authors:  Ronit Shtrichman; Douglas M Heithoff; Michael J Mahan; Charles E Samuel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection.

Authors:  M Eisenberg; S Rosno; G Garcia; M W Konrad; P B Gregory; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.